FDA clears absorbable soft-tissue marker from Augmenix

01/29/2013 | AuntMinnie.com (free registration)

The FDA has given Augmenix 510(k) clearance to market TraceIT, an injectable synthetic hydrogel used to mark soft tissue radiographically before surgery. The technology, which can be viewed through MRI and other ultrasound modalities, is designed to help streamline image fusion and enhance soft-tissue alignment.

View Full Article in:

AuntMinnie.com (free registration)

Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
Counsel – Regulatory Affairs
RAI Services Company
Winston Salem, NC
Director of Program Development
AdvaMed
Washington DC, DC
Director of System QA
LifeWatch Services, Inc.
Rosemont, IL
Director of Business Development and Membership
AdvaMed
Washington DC, DC
Director, Corporate Counsel
Regeneron
Tarrytown, NY